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Abstract
Purpose
The purpose of the research was to identify the clinical and commercial benefits of
switching from intravenous (IV) to buccal delivery of antibiotics. then, the research
continued to select 3-5 antibiotics that best met the buccal delivery and market
requirements.
Methods:
The research began with the hypothesis that some injectable antibiotics are good
candidates for buccal delivery even with the limitations imposed by the buccal tissue.
The thesis captures a two-year research period encompassing three critical fronts - the
clinical viability of switching from IV to buccal delivery for antibiotics, the market's desire
and readiness to switch, and the antibiotic brands available for commercialization. Then
the research moved to drug identification and selection in order to assess the antibiotics
that would best function in the buccal delivery model.
Results:
Intravenous (IV) antibiotics are usually reserved for severe infections that require faster
treatment. Less aggressive bacterial growths are treated with oral antibiotics, which has
fewer side effects and complications. In the past two decades, the understanding of
drug transport across different tissues has increased resulting in improved patient
adherence to the therapeutic regimen and pharmacologic response. The administration
of drugs by transdermal or transmucosal routes are relatively painless, offers patients
more choices, and reduces the need to establish intravenous access, which is a
particular benefit for children and elderly. These alternative methods also provide
clinical care providers with more choices to better manage their patient's course of
treatment. In the past, clinicians administered sedatives, narcotics, and a variety of
other medications by transdermal, sublingual, nasal, rectal, and even tracheal-mucosal
routes. These delivery options have provided flexible practice settings and this paper
intends to show that antibiotics could be the next set of drugs to be administered in
variety of ways to provide patients and clinicians the best array of choices.
Conclusion:
A few years ago, the buccal delivery method was fairly unknown. However, advances in
nano encapsulation, physiology, toxicity, and the availability of certain drugs make the
timing ideal for introducing antibiotics that have undergone a highly selective process for
delivering through the buccal tissue.
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Chapter 1: Introduction
Intravenous (IV) antibiotics are usually reserved for severe infections, which require
faster treatment. Lesser bacterial growths are treated using oral antibiotics, which carry
fewer side effects and chances for complications. The risks associated with the use of
IV antibiotics, including the development of drug-resistant bacteria, make it necessary
for clinical care givers to restrict their use.
According to "General Standards of IV Therapy" guide, if the patient is suffering from a
non-life threatening illness, the benefits of using IV methods of treatment versus oral
medication should be weighed against the potential serious side effects. Furthermore,
the guide stipulates the need to explain to the patient the risks and benefits inherent in
the two methods for delivering antibiotics so that the patient is able to make and
decision E1. This thesis focuses on the possibility of using oral antibiotics as the
preferred method of delivery due to the apparent benefits of risk reduction and patient's
well being.
In the past two decades, the understanding of drug transport across different tissues
has increased resulting in improved patient adherence to the therapeutic regimen and
pharmacologic response. The administration of drugs by transdermal or transmucosal
routes are relatively painless and provides patients with ease of use, and reduces the
need for intravenous access, which is of particularly benefit for children and the elderly
[3]. These alternative methods also provide practitioners more choices to better manage
their patient's course of treatment [51.
Historically, clinicians have administered sedatives, narcotics, and a variety of other
medications via transdermal, sublingual, nasal, rectal, and even tracheal-mucosal
routes thereby effectively increasing delivery options and increasing both patient and
clinician choice [191. This paper intends to demonstrate that antibiotics can become the
next set of drugs to be administered in variety of ways and provide patients and
clinicians with a similar array of choices. The ultimate aim of this thesis paper is to
investigate the possibility of creating patient-friendly antibiotic buccal patches to
substantially improve patient compliance, reduce hospital stay, and significantly
decrease the devastation and health care costs of medical complications due to hospital
associated infections (HAls). This paper's primary focus is the delivery of certain
antibiotics in buccal patches, where it is believed they will have immediate and lasting
positive impact given the current therapeutic landscape. This investigation is the first
step toward research and development of an effective, safe medicated buccal patch that
can easily be shipped anywhere in the world, is simple to use, easy to understand
dosing, convenient to carry, does not require refrigeration and has a long shelf life. The
patch can help millions of patients around the globe who fear needles or have limited
access to clinics, needles, and refrigeration.
This paper provides guidelines and criteria for the selection of antibiotic candidate
drugs. Some of these requirements are based on the mechanical and biochemical
properties of the physical delivery device, which in this case is the buccal patch. The
properties include: 1.The efficacy of release triggers such as the biochemical properties
of the saliva, mouth pH and optimal release of the antibiotic within the nano particles. 2.
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The interdisciplinary aspects of the mechanical capacity and biological attributes of the
nanoparticles to contain the required amount of drugs. 3. Effect of environmental
variables such as humidity, light, and temperature on the mechanical and biochemical
integrity of the nano particles, the drugs, and base materials used in the dissolvable. 4.
The mechanical and biological impact of the permeation enhancers on the oral cells as
well as the fat and muscle cells. 5. The time needed to effectively release the specified
amount of the drug and meet the medical bioavailability requirements.
The findings reflected in this thesis are based on two years of academic, clinical, and
market research. The academic component of the research focused on better
understanding the impact of the buccal delivery method of human physiology when
compared to the IV delivery methods. The market research component focused on the
benefit to patients, physicians, and hospitals. The marketing component focused on
antibiotics currently on the market that fit the standards established for antibiotics that
can be used in the buccal delivery method. The conclusions of the research so far lead
the author to believe that the buccal delivery system presents lower risks to patients, is
more cost effective for hospitals, and can be used with some highly selected antibiotics
currently on the market that fit the criteria established by the research protocol.
The following diagram illustrates the various action steps in the research process. It
also describes the relationships among the steps.
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Figure 1: The Strategies used to complete this thesis
The thesis is organized in the following manner:
9 Chapter 2: General Overview of Buccal Delivery and Antibiotics
Chapter 2 covers why buccal delivery is an attractive drug delivery choice to
researchers and pharmaceutical companies. It also gives an overview on antibiotics,
bacteria resistance and what class of antibiotics is the focus of this thesis.
e Chapter 3: General Side Effects of IV therapy
Chapter 3 covers the infections associated with IV therapy and contamination of the
catheter hub that contribute substantially to intraluminal colonization of long-term
catheters. It explains the training that is required by the clinicians to reduce infection
risks caused by injection.
* Chapter 4: Mucosa Membrane
Chapter 4 describes the properties of mucosa membrane and then focuses on the
buccal mucosa and administration of drugs via this membrane to the systemic
circulation. It covers the anatomy and physiology of oral mucosa and help the reader
understand why the buccal region can be a used for drug delivery.
e Chapter 5: In-depth analysis of Buccal Drug Delivery
Chapter 5 describes the concepts and compounds used to increase the efficacy of the
buccal mucosa. It discusses how mucoadhesive polymers and permeation enhancers
can be useful in making buccal delivery a viable alternative to oral and IV delivery
techniques. It also describes the advantages and disadvantages of the buccal delivery
methods.
* Chapter 6: Buccal Delivery Drugs and Patches
This chapter focuses on the drug characteristics that are important for buccal drug
delivery. It also exhibits the known formulations used for increasing bioavailability and
lists FDA approved drugs that are currently delivered via this method. Finally it covers
the design of buccal patches that are well suited for drug delivery.
& Chapter 7: Antibiotic Marketing and Business Requirements
This chapter discusses the key marketing and business elements for successful
commercialization of buccal antibiotics. It discusses why buccal delivery is an effective
response to clinical needs based on research by CDC and Frost and Sullivan's reports.
* Chapter 8: Requirements for this research
This chapter covers the business, scientific and clinical considerations of this research.
It also lists the buccal delivery considerations that we used in this research to help
narrow down the selection of suitable antibiotics. There is a table in this chapter that
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shows some of the antibiotics that were investigated and the elements that were used to
eliminate some for buccal patch delivery.
9 Chapter 9: Final Drug Candidates
This chapter covers the 4 antibiotics and one osteoporosis drug that meets the research
requirements of this thesis.
" Concluding Remarks
e References
" Appendices: Additional information that exhibits how we conducted the research
and made some of our conclusions.
Chapter 2: General Overview of Buccal Delivery and Antibiotics
Why Buccal Delivery?
The most commonly employed route for the administration of medications is the peroral
route but, due to the limitations associated with the peroral route such as extensive first-
pass metabolism and hydrolysis of acid-labile drugs, the potential use of other routes of
drug administration such as the buccal need to be investigated [.
Drug delivery forms such as tablets, gels, solutions, and patches can be placed in the
buccal pouch 31] .Modifications can be made to the buccal tissue's permeability or to the
local environment of the mouth to allow absorption of the active dug into the blood
circulation. Drug delivery via the buccal mucosa is rapidly emerging due to the fact that
this route of delivery possesses many advantages over the other routes, which involve
extensive first-pass metabolism. Even compared to the other mucosal and transdermal
routes of delivery, the buccal mucosa appears to be better in terms of permeability,
surface area, patient compliance. Another advantage of the buccal mucosa is that it is
more resistant to tissue damage and irritation since it is frequently exposed to different
types of food with variety of pH levels. Its cell turnover, when compared to other
mucosal routes of administration, is also very rapid, which makes it heal quickly. Hence
the buccal route of delivery is the logical alternative delivery route for drugs which, if
delivered orally undergo extensive degradation in the stomach and liverl7'ai
Overview of Antibiotics
"The first rule of antibiotics is to try not to use them, and the second rule is try to not to
use too many of them" [333
-Paul L. Marino, The ICU Book
An antibiotic is used synonymously with antibacterial and is a compound that kills or
slows down the growth of bacteria [2. With the increased understanding of infectious
diseases, the definition of antibiotic has been broadened to include antimicrobial
compounds, anti-fungal and other compounds[31
In 1942, Selman Waksman defined "antibiotic" as a substance created by a
microorganism that is antagonistic to the growth of other microorganisms in high
dilution. This definition excluded substances such as gastric juices and hydrogen
peroxide that kill bacteria but are not produced by microorganisms. The definition also
excluded compounds such as sulfonamides, which are synthetic antibacterial. Many
antibacterial compounds are relatively small molecules with a molecular weight of less
than 2000 atomic mass units [13].
With advances in medicinal chemistry, most of today's antibiotics are semi-synthetically
created by modifying natural compounds. For example, beta-lactam antibacterials
include the penicillin, the cephalosporins, and the carbapenems. Compounds that are
still isolated from living organisms are the amino glycosides, whereas other
antibacterials such as the sulfonamides, the quinolones, and the oxazolidinones, are
produced solely by chemical synthesis [14. Accordingly, many antibacterial compounds
are classified on the basis of chemical/biosynthetic origin into natural, semi synthetic,
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and synthetic. Another classification uses antibiotics biological activity; which are
divided into two broad groups based on their biological effect on microorganisms:
bactericidal agents kill bacteria, and bacteriostatic agents slow down or stall bacterial
growth [14].
In this thesis, the focus is on broad-spectrum antibiotics since they are more widely
used in current clinical settings. The term broad-spectrum antibiotic refers to an
antibiotic that acts against a wide range of disease-causing bacteria. A broad-spectrum
antibiotic such as ampicillin fights both Gram-positive and Gram-negative bacteria,
which is unlike the narrow-spectrum antibiotic, which works against a specific family of
bacteria[4]
This thesis also considers issues associated with bacterial resistance, which can be
magnified if bioavailability of the antibiotic is poor. The striking, widespread increase in
bacterial resistance to antibiotics is an issue of great concern. Worldwide emergence of
antibiotic resistance in common gram-positive coccal pathogens is probably the most
devastating issue in the bacterial infection landscape. The most important of these
organisms are penicillin-resistant Streptococcus pneumonia, vancomycin-resistant
Enterococcus, and methicillin- (and now vancomycin-) resistant Staphylococcus aureus.
Although known by the above names, all of these organisms are multidrug-resistant.
Beta-lactam and vancomycin resistances in gram-positive cocci are caused by altered
cell wall binding sites with decreased affinity for the drug. Another serious problem is
that of resistance in certain gram-negative bacilli due to extended-spectrum beta-
lactamase production [311
Chapter 3: General Side Effects of IV Therapy
IV therapy can sometimes cause minor issues such as irritation or pain at the site of
injection due to yeast over growth. More specifically, IV antibiotics may also be given in
much higher doses due to the patient condition, severity and/or type of infection. For
instance, pregnant women are given IV medication for group B strep bacteria because
oral versions do not effectively kill the bacteria in the vagina to offer protection for the
baby [9].
Migration of skin organisms at the insertion site into the cutaneous catheter tract with
colonization of the catheter tip is the most common route of infection for peripherally
inserted, short-term catheters. Contamination of the catheter hub contributes
substantially to intraluminal colonization of long-term catheters [5].
When selecting vascular access devices and treatment regimens, it is important to
consider the patient's lifestyle as well as clinical situation. For example, younger
patients have different needs and considerations comparent to older patients who are
geriatrics. Some individuals have access to supportive careers while others are socially
isolated. Some patients have the mental capacity and manual dexterity to be involved in
their infusion therapy while others may not [4,5 . These factors, as well as those unique
to the patient's particular case, need to be taken into consideration when assessing for
infusion therapy. Registered nurses undertaking the insertion of vascular access
devices must undergo theoretical and practical training in the following [5]-
" Anatomy and physiology of the circulatory system, in particular, the anatomy of
the location in which the device is placed including veins, arteries and nerves and
the underlying tissue structures
" Assessment of patients' vascular access needs, nature and duration of therapy
and quality of life
" improving venous access, for example the use of pharmacological and non-
pharmacological methods
" Selection of veins and problems associated with venous access due to
thrombosed, inflamed or fragile veins, and the effects of ageing on veins, disease
process, previous treatment, lymphoedema or presence of infection
" Selection of device and other equipment
" Infection control issues (hand-washing, skin preparation)
* Pharmacological issues (use of local anesthetics, management of anxious
patients, management of hematoma, phlebitis, etc.) In the event of tenderness at
the site, fever without an obvious source, symptoms of local or systemic
infection, or the presence of exudates, the dressing should be removed and the
site assessed.
* Documentation in the patient's nursing notes should reflect routine assessment
and describe the condition of the insertion site.
* Patient education regarding dressing care and maintenance should be
documented in the patient's notes [.
Chapter 4: Mucosa Membrane
Buccal delivery relies on the properties of mucosa membranes found in the mouth.
Mucosa Membranes are linings that are of endodermal origin. These linings are covered
in epithelium and are responsible for absorption and some secretion. Body cavities that
are exposed to the external environment and internal organs are lined with mucosa
membrane17 ,81.Several places in the body have continuous mucosa with skin - at the
nostrils, the lips, the ears, the genital area, and the anus. The sticky thick fluid secreted
by the mucous membranes and gland is termed mucus 181.
Different absorptive mucosa membranes, such as nasal, rectal, vaginal, ocular and oral
cavity, are considered as potential sites for noninvasive systemic administration, local
targeting / systemic drug delivery 119.These drug delivery systems utilize property of bio-
adhesion of certain water soluble polymers which become adhesive on hydration and
therefore can be used for targeting particular sites. Buccal delivery is the administration
of the drug via buccal mucosa (lining of the cheek) to the systemic circulation 181.
Types of Mucosa
1. Buccal mucosa
2. Esophageal mucosa
3. Gastric mucosa [8]
4. Intestinal mucosa
5. Nasal mucosa
6. Olfactory mucosa
7. Oral mucosa
8. Bronchial mucosa
9. Uterine mucosa 781
Anatomy and Physiology of Oral Mucosa
A thick dense & multilayered mucous membrane lines the oral cavity. This lining is
highly vascularized. Drug penetrating into the membrane passes through a network of
capillaries & arteries and reaches the systemic circulation [5].
There are mainly three functional zones of oral mucosa:
1. Masticatory mucosa : Covers gingival hard palate regions, keratinized
epithelium
2. Mucous secreting region: Consist of soft palate, floor of mouth underside of
tongue & buccal mucosa. This region shows non-keratinized mucosa.
3. Specialized mucosa : consist of lip border & dorsal surface of tongue with
high selective keratinization [8]
Components of Oral Mucosa
1. Epithelium
2. Lamina propria
- Smooth muscle/Muscularis mucosa/ GI tract [7]
Oral epitheblum
Basement membrane
Lamina propia
- contains blood vessels
and nerves
- Muscle or bone
Figure 2: Schematic Diagram of Buccal Mucosa [4]
of Tongue
Floor d Mouth
Lower LP
*Mastictory Mucosa
Lining Mucosa
Speciaized Mucosa
Figure 3: Schematic Diagram of the Mouth shows the anatomic location and extent of Masticatory, lining, and
specialized mucosa in the oral cavity [381.
Region
Skin (mammary region)
Hard palate
Buccal mucosa
Floor of mouth
Average epithelial thickness (urn)
100 - 120
250
500-600
100-200
Table 1: Different Epithelial and their thicknesses [71
Chapter 5: In-Depth Analysis of Buccal Drug Delivery
Concepts of Buccal Drug Delivery System
Mucoadhesive polymers are drug delivery vehicles. The common principle underlying
this drug administration route is the adhesion of the dosage form to the mucous layer
until the polymer dissolves or the mucin replaces itself. Benefits for this route of drug
administration are: prolonged drug delivery, targeted therapy and often improved
bioavailability [7].
Biological membrane, the membrane of internal tract such as GI Track, buccal cavity,
eye, nose,vagina, and rectum, are covered with a thick gel like structure know as mucin.
All biological formulation interacts with mucin layer during process of attachment. It acts
as a link between the adhesive and the membrane [7]
Mucous is a network of mucin glycoprotein that forms a continuous layer that intimately
covers the internal tract of body. Total weight of mucous secreted by globlet cell only
contain less than 5% of glycoprotein. There are about 160-200 oligosaccharides side
chain in the glycosylated region of the glycoprotein.
Each oligosaccharides unit has 8-10 monosaccharides and terminal end of either sialic
acid or L-fucose. Mucin have network of negative charge due to sialic acid, and sulfate
residue. The bioadhesion mainly depends upon the nature of bioadhesive polymer. First
stage involves an intimate contact between a bioadhesive & a membrane. Second
stage involves penetration of the bioadhesive into tissue. At physiological pH the
mucous network may carry negative charge because of presence of sialic acid & sulfate
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residue and this high charge density due to negative charge contributes significantly to
bioadhesion [8.
Advantages of Buccal Drug Delivery Systems
1. Termination of therapy is possible
2. Permits localization of drug to the oral cavity for extended period of time.
3. Ease of administration
4. Avoids first pass metabolism.
5. Reduction in dose can be achieved, thereby reducing dose dependent side
effects
6. Allows for local modification of tissue permeability, inhibition of protease
activity or reduction in immunogenic response, thus selective use of
therapeutic agents like peptides, proteins and ionized species can be
achieved.
7. Drugs that are unstable in the stomach's acidic environment or destroyed by
the intestine's alkaline environment can be given by this route.
8. Drugs that show poor bioavailability by oral route can be administered by this
route.
9. It follows passive diffusion and does not require any activation
10. The presence of saliva ensures large amount of water for dissolution of drug
unlike in case of rectal and transdermal route [8].
11. Drugs with short half life can be administered by this method. (2-8 hrs) e.g.:
nitroglycerine (2 hrs) isosorbide mononitrate (2-5 hrs)
12. From the formulation point of view, a thin mucin film exists on the surface of
oral cavity.
13. Provides opportunity to retain delivery system in contact with mucosa for
prolonged period of time with the help of mucoadhesive compounds.
14.The buccal membrane is sufficiently large to allow delivery system to be
placed at different sites on the same membrane for different occasions, if the
drug or other excipients cause reversible damage or irritate mucosa [al
Disadvantages of Buccal Drug Delivery Systems
1. Over hydration may lead to formation of slippery surface & structural integrity
of the formulation may get disrupted by the swelling & hydration of the
bioadhesive polymer.
2. Eating and drinking may become restricted.
3. There is possibility that the patient may swallow the tablet [81.
4. The drug contained in swallowed saliva follows the peroral route thereby
losing the advantages of the buccal route.
5. Only drug with small dosing requirements can be administered.
6. Drugs that irritate mucosa, have a bitter and/or unpleasant taste, or an
obnoxious odor cannot be administered by this route [8].
7. Drugs that are unstable at buccal pH cannot be administered by this route.
8. Only those drugs which are absorbed by passive diffusion can be
administered by this route [8]-
Chapter 6: Buccal Delivery Drugs and Patches
Drug Characteristics for Buccal Drug
1. Molecular size - 75-600 daltons
2. Molecular weight between 200-500 daltons.
3. Drug should be lipophilic or hydrophilic in nature.
4. Stable at buccal pH.
5. Taste - bland
6. Drug should be odorless.
7. Drugs absorbed only by passive diffusion should be used [8.
Formulations used for buccal delivery
Photo of different formulations [17]
Oral bioadhesive formulation
1. Corlan - hydrocartisone succinate
2. Bonjela - hypromellose
3. Taktarin - miconazole[8l
4. Corsodyl - chlorohexidine 8 ]
Buccal mucosa drug formulation
1. Buccaten - nausea , vomiting, virtigo 8 ]
2. Suscard - angina
3. Oxytocin Buccal Tablets (too large to be administered sublingually)[181
Sublingual formulation
1. GTN (Glycerin Trinitrate) E8]
Permeability Enhancer formulation
Permeability enhancers are substances added to pharmaceutical formulation in order to
increase the membrane permeation rate or absorption rate of co-administered drug.
They can enhance the drug's bioavailability by 5% to 40%. The limiting factor in using
strong permeation enhancers is the potential for membrane damage. For example the
permeability of fluorescein isothiocynate (FITC) has increased 100-200 fold compared
to FITC alone by simply using di- and tri-hydroxyl bile salts as a permeation enhancer 1 .
Design of Buccal Dosage Form
Buccal Patches
The use of polymeric patches for buccal delivery has not yet been widely investigated,
although they have been extensively employed in the modification of the drug release
and their protection by way of coating and matrix formation in various solids like tablets,
pellets, granules and powders. An ideal buccal patch should be flexible, elastic and soft
yet adequately strong to withstand breakage due to stress from mouth activities.
Moreover, it must also exhibit good mucoadhesive strength so that it can be retained in
the mouth for a desired duration. As such, the mechanical, mucoadhesive, and swelling
properties of buccal patches are critical and essential to be evaluated [7, 8].
As mentioned before, the buccal route has high acceptance due to avoidance of first
pass metabolism and possibility of being accessible for controlled drug release. Buccal
patches are preferred over adhesive tablets in terms of flexibility and patients comforts.
A suitable buccal drug delivery system should be flexible and possess good
bioadhesive properties, so that it can be retained in the oral cavity for the desired
duration. In addition, it should release the drug in a predictable manner to elicit the
required therapeutic response [31].
Buccal patches are laminates that could contain an impermeable backing layer, a drug-
containing reservoir layer, and a bioadhesive surface for mucosal attachment, which are
similar to those used for transdermal drug delivery. Backing layer control the direction of
drug release, prevent drug loss, minimize deformation and disintegration [31].
a1k t
Antibiotic Layer Adhesive layer Backing Layer Patch
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--- Backing layer
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Figure 4: Schematic diagram: (a), photographic image (b), and schematic cross-sectional diagram (c) of a
Mucoadhesive patch comprising drug 1
Matrix Type
The Buccal patch designed in a matrix configuration contains drug, adhesive, and
additives mixed together. Bi-directional patches release drug in both the mucosa and
the mouth. The structure of the matrix type design is basically a mixture of the drug with
the mucoadhesive matrix.
Reservoir Type
The buccal patch designed in a reservoir system contains a cavity for the drug and
additives separate from the adhesive. Impermeable backing is applied to control the
direction of drug delivery; to reduce patch deformation and disintegration while in the
mouth; and to prevent drug loss.
Other buccal delivery methods
Buccal Films
This is a recent method of buccal drug delivery which is more user friendly than the
buccal adhesive tablet. It is beneficial for oral diseases because of its strength,
softness, adhesiveness and flexibility.
Buccal Gels
These semisolid dosage forms are easy to disperse throughout the oral mucosa but are
not as accurate as tablets, patches, or films. Poor retention of the gels at the site of
application has been managed by using bioadhesive formulations.
Challenges of Buccal Delivery
Oral transmucosal and the environment of the oral cavity present some significant
challenges for systemic drug delivery. In order for the drug to enter the systemic
circulation it needs to be released from the formulation to the delivery site (e.g. buccal
or sublingual area) and pass through the mucosal layers [8]
Drug Encapsulated Nano particles
The following figure shows the three stages of drug delivery via nano encapsulation
encapsuhate the encaltro d thee h oa
pharmaceutical agent &ecpuae
permeation enhancers /-formulation to the oral Pucosa
Figure 5: Nano Encapsulation & Release
Drug permeation is impacted by the certain physiological aspects of the oral cavity [8]
such as:
1. Oral cavity's mucosa health and age
2. Fluid volume
3. Enzyme activity
For extended release drug delivery the following are major factors [8]:
1. mucoadhesivity
2. Structure of the mucosa surface area
3. Turnover of the mucosa cells more
Absorptive Estimated Percent Local pH Mean fluid Relative Relative
site surface total volume enzyme drug
area surface (ml) activity absorption
area capacity
Oral cavity 100 cm2 0.01 5.8-7.6 0.9 Moderate Moderate
(0.01 m2)
Stomach 0.1-0.2 m2  0.20 1.0-3.0 118 High Moderate
Small 100 m2  98.76 5.0-7.0 212 High High
intestine
Large 0.5-1.0 m2  0.99 6.0-7.4 187 Moderate Low
intestine
Rectum 200-400 0.04 7.0-7.4 - Low Low
cm2 (0.04
m2m 2)
Table 2: Comparison of different mucosa [i
Table 2 shows the comparison between buccal mucosa with the mucosa of the GI tract
based on their physiological characteristics [7].
Role of saliva and mucus in the buccal delivery
As mentioned earlier, saliva produced in the oral cavity plays a key role in the drug
permeation. Therefore, it is important to understand the function and variability of saliva
and its producing glands. The main functions of saliva are to lubricate the oral cavity,
facilitate swallowing, and prevent demineralization of the teeth. Saliva allows
carbohydrate digestion and regulates oral microbial flora by maintaining the oral pH and
enzyme activity. Saliva's pH significantly influences the drug permeability and is
considered a weak buffer with a pH around 5.5-7.0 [.
Salivary glands produce mucus, which surrounds the oral epithelia cells. The mucus
complexes are made up of proteins and carbohydrates; with thickness ranging from 40
to 300 pm. In the oral mucosa, mucus is secreted as part of saliva by the major and
minor salivary glands and is mostly made up of water. However, it has key
macromolecular glycoprotein components known as mucins (1-5%). Mucins contain
large amounts of carbohydrate with molecular mass ranging from 0.5 to over 20 MDa
and are made up of basic units (=400-500 kDa) linked together into linear arrays
forming an extended three-dimensional network [71. Mucins act as a lubricant allowing.
Mucins act as a lubricant allowing cells to move relative to one another, and may also
contribute to cell-cell adhesion. The mucus network is negatively charged due to the
sialic acid and sulfate residues and forms a strongly cohesive gel structure that will bind
to the epithelial cell surface as a gelatinous layer- It is believed that this gel layer
extends the dosage form retention time at the delivery site thereby allowing the drug to
stay stationary longer [2,.
The following are some of the relative facts about saliva:
Major salivary glands in the oral cavity are
1. Parotid (watery secretion)
2. Submaxillary (watery secretion)
3. Sublingual (viscous saliva with limited enzymatic activity)
Minor salivary glands [8]
1. Buccal glands (right below the mucosa)
Saliva volume:
1. Daily secretion volume: 0.5 to 2.0 liter
2. Constant volume present in the mouth: 1.1 milliliter
3. Lower volume and less viscous compared to GI fluid 81
The flow rate of saliva which determines the oral cavity's pH and salivary compositions
are dependent on [8]:
1. Time of day,
2. Type of stimulus
3. Degree of stimulation.
High flow rates of saliva, causes increase of sodium and bicarbonate concentrations
which in turn increases the pH of the oral cavity. The water rich environment in the oral
cavity can be favorable for the release of the drug from delivery systems especially
those that are based on hydrophilic polymers, but too much flow can lead to premature
swallowing of the drug before effective absorption occurs through the oral mucosa
called "saliva wash out'[2,37
Oral Mucosa Permeation
Drug permeability through the oral (e.g. buccal/sublingual) mucosa is another major
physiological barrier for oral transmucosal drug delivery. The thickness of oral mucosal
and the composition of the epithelium vary depending on the site [7,37]
The characteristics of the different regions of interest in the oral cavity are shown in
Table 3.
Tissue Structure Thickness Turnover Surface Permeability Residence Blood flow
(pm) time area time(days) (cm2±SD
Buccal NK 500-600 5-7 50.2±2.9 Intermediate Intermediate 20.3
Sublingual NK 100-200 20 26.5±4.2 Very good Poor 12.2
Gingival K 200 - - Poor Intermediate 19.5
Palatal K 250 24 20.1±1.9 Poor Very good 7.0
Table 3: Different Tissues in the oral cavity 1
Note that mechanical stress on different areas of mucosa impacts the keratinization
characteristic of the area. For example the mucosa of the soft palate, sublingual and
buccal regions are not keratinized which makes them more suitable for drug delivery.
The neutral lipids in keratinized epithelia are associated with the barrier function which
makes them relatively impermeable to water. In contrast, non-keratinized epithelia, such
as the floor of the mouth and the buccal epithelia do not contain acylceramides and only
have small amounts of ceramides which makes them more permeable to water. They
have neutral but polar lipids, mainly cholesterol sulfate and glucosyl ceramides. [7].
There intercellular materials derived from the so-called membrane coating granules
(MCGs) contribute to the relative impermeability of the oral mucosa. MCGs organelles
(100-300 nm in diameter) are found in keratinized and non-keratinized epithelia.
Cultured oral epithelium without MCGs is more permeable for delivery of compounds
than normal epitilium. Also permeation studies with the use of tracers show that tracer
molecules cannot penetrate below the top 1-3 layers of normal epithelium where MCGs
are observed. When the same tracer molecules were introduced sub-epithelially, they
penetrated through the intercellular spaces. This same pattern is observed in both
keratinized and non-keratinized epithelia, which indicates that MCGs are more
significant to permeation compared to the keratinization of the epithelia. Another factor
of the buccal epithelium that can affect the mucoadhesion of drug delivery systems is
the turnover time [7]* As mentioned above mucus is a key contributor to the
mucoadhesion but so is the turnover time. The turnover time for the buccal epithelium is
estimated to be 3-8 days compared to about 30 days for the skin [7]- The turn over time
also contributes to the resilience of the mucosa's epithelium layer since it can recover
quickly from damages caused by minor drug irritations. There are about 40 - 50 layers
of cell in the buccal mucosa, resulting in about 500 - 600 pm thick [2, 37]. The following
figures illustrate the drug absorption mechanisms and approaches for the delivery of
drugs through the oral mucosa.
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Figure 7, Drug Delivery Approaches [
Buccal Delivery Verses Oral Delivery for Replacing Injection
The oral delivery remains the preferred route for drug administration due to its low cost,
ease of administration and high level of patient compliance. However due to the
significant restrictions of drug delivery within the gastrointestinal (GI) tract, other
absorptive mucosae are being considered as potential sites for drug administration
including the mucosal linings of the nasal, rectal, vaginal, ocular, and oral cavity. These
transmucosal routes of drug delivery offer distinct advantages over peroral
administration for systemic drug delivery such as the possible bypass of the first pass
effect and avoidance of presystemic elimination within the GI tract. Amongst these, drug
delivery to the oral cavity has attracted particular attention due to its potential for high
patient compliance and unique physiological features [7, 81.Within the oral mucosal cavity,
the delivery of drugs can be classified as follow:
1. Local delivery
2. Systemic delivery either via the buccal or sublingual mucosa [8]
Despite the challenges of systemic delivery via oral mucosa, this area has unique
structural and physiological properties. The properties offer several opportunities for
effective delivery of certain class of drugs to the blood stream [8]. As the mucosa is
highly vascularized and any drug diffusing across the oral mucosa membranes has
direct access to the systemic circulation via capillaries and venous drainage and will
bypass hepatic metabolism. As shown in table 3, the rate of blood flow through the oral
mucosa is substantial, and is generally not considered to be the rate limiting factor in
the absorption of drugs by this route .
The following list is the summary of some of the challenges with oral drug delivery:
1. For oral delivery through the GI tract, the drug undergoes a rather hostile
environment before absorption
2. GI track includes drastic changes in pH (from pH 1-2 in the stomach to 7-7.4
in the distal intestine)
3. GI transit is unpredictable, caused by the presence of numerous digestive
enzymes and intestinal flora[8'
Unlike this harsh environment of the GI tract, the oral cavity offers relatively consistent
and friendly environment for drug delivery which include some of the following
conditions:
1. Continuous secretion of saliva.
2. Saliva is a relatively mobile fluid with less mucin than the Gl tract
3. Limited enzymatic activity
4. Almost no protease in the oral cavity [8].
The degradation of protein and peptide due to GI track's enzymes is a major concern for
oral drug delivery. In comparison, the buccal and sublingual regions have less enzymes
and lower enzyme activity. It is believed that the buccal mucosa is exposed to mainly
some aminopeptidases, carboxypeptidases which are relatively mild compare to the GI
track enzymes.
Despite the tremendous advances in the oral mucosa drug delivery, the oral-GI route
remains the preferred route for drug administration due to its low cost, ease of
administration and high level of patient compliance. However, this review examines the
physiological considerations of the oral cavity in light of systemic drug delivery and
provides an insight into the advances in oral transmucosal delivery systems.
Name of Drug Transport Mechanism Pathway Tissue
5-Aza-2'-deoxycytidine Passive Not Defined Buccal mucosa
2', 3'- dideoxycytidine Passive Not Defined Buccal mucosa
Flecainide Passive Paracellular Buccal mucosa
Sotalol Passive Paracellular Buccal mucosa
Nicotine Passive Paracellular, TR146 Cell culture andTranscellular buccal mucosa
Lamotrigine Passive Transcellular Buccal mucosa
Galantamine Passive Not Defined Human oral epithelium andbuccal mucosa
Naltrexone Passive Not Defined Buccal mucosa
Buspirone Passive Transcellular Buccal mucosa
Ondansatron HCI Passive Buccal mucosaCarrier Mediated Buccal mucosa
Monocarboxylix acids Carrier Mediated Carrier Mediated Primary cultured epithelialcells
Glucose Carrier Medicated Carrier Mediated Buccal, oral mucosal cellsand dorsum of tongue
Table 4: Examples of Drugs Transported via Different Mechanisms through Buccal Mucosa [7
To maintain antimicrobial activity, antibiotics with short half-life is should be frequently
administered. If not followed concentration under MIC (minimum inhibitory
concentration) occurs frequently in the course of anti-infective treatment, which induces
antibiotic resistance. By maintaining a constant plasma drug concentration over MIC for
a prolonged period, extended-release dosage forms maximize the therapeutic effect of
antibiotics while minimizing antibiotic resistance. Another undoubted advantage of
extended-release formulation is improved patient compliance 32]. The buccal delivery
can support extended antibiotic delivery relative to oral delivery to reduce the chance
antibiotic resistance, however since the bioavailability is not as good as intravenous
delivery, there is always a chance that the amount of antibiotic delivered via the buccal
tissue is not adequate relative to IV delivery. Ultimately to better measure and
understand the challenges and benefits of the buccal antibiotic delivery, PK/PD studies
need to be performed (see Appendix G for details) [361
As mentioned above the bioavailability of the drug via the buccal tissue is not very high,
even with the addition of permeation enhancers and Mucoadhesive compounds to the
drug composition, the bioavailability of buccal delivery could be only about 20% of the
intravenous (IV) delivery. To cause the same effect as IV delivery, there needs to be
80% more antibiotic in the buccal area which offers problems such as toxicity and cost.
Some of the broad spectrum IV antibiotics on the market require large doses and these
drugs due to the bioavailability limitations of mucosa membrane will not be good
candidates for buccal delivery. Many of these antibiotics are also very costly about $400
per dose which would also be a barrier to entry for buccal delivery due to the limited
bioavailability [2, 7]. The other limiting factor for some antibiotics is that the patch or oral
mucosa delivery devices can contain small amounts of drugs so we assumed maximum
11 mg of drugs. The matrix limitation and nano encapsulation of the drug contribute to
this limitation.
If the antibiotic's side effects include tissue irritation then buccal delivery might not be
good delivery method for that antibiotic.
Chapter 7: Antibiotic Marketing and Business Requirements
This thesis's Marketing Consideration
This research takes in to consideration the following key marketing and business
elements for selecting the best antibiotics for buccal delivery:
- Market size for the injectable antibiotics
- Patient Eligibility
- Cost
- Availability
- Location
- Regulatory Landscape:
- guidelines
- Important stakeholders
o Existing products
o Locality of trials
- US based
- Developing countries
o Emerging policies
o Relevant precedents
- End customer:
o Hospitals
o Insurance companies
o Company Investors
o Care givers
o Patients
Market Need
Microbial natural products are the origin of most of the antibiotics on the market today.
However, research in antibiotics and natural products has declined significantly during
the last decade as a consequence of diverse factors and has caused an alarming
scarcity of new antibiotic classes in the pipelines of the pharmaceutical industry [1]
Looking into the future demands for antibiotics; now is a great time to investigate and
start businesses around antibiotics to meet the upcoming demands [1.
Moreover, several popular antibiotics are coming off patent and there is an interest in
the pharmaceutical market to extend their existing patents' life through alternative drug
delivery techniques. Based on our research, offering these companies alternative and
reliable buccal delivery of their antibiotics would be of great value.
Buccal Delivery - An Effective Response to Clinical Needs
Healthcare-associated infections (HAl) result in excess length of stay, mortality and
healthcare costs. In 2002, an estimated 1.7 million healthcare-associated infections
occurred in the United States, resulting in 99,000 deaths. In March 2009, the CDC
released a report estimating direct medical costs of healthcare-associated infections
that ranged from $28-45 billion annually [6]
o In the US alone, bloodstream infections are the 8th cause of death.
o Prevention from infection is a major focus of healthcare providers, because
risk of death from bacteremia or fungemia is very high.
o According to CDC, 35 million patients are annually admitted to 7000 US
based acute-care units.
o Since infection is the most common serious complication of intravascular
catheters causing high morbidity and mortality the benefits derived from these
devices are seriously being questioned.
o Most catheter-related infections are caused by staphylococci, originating from
the skin of the patient and migrating along the external surface of the
catheter[)..
o Prolonged duration of catheter placement, frequent manipulation of the
catheter and use of thrombogenic catheter material increase the risk of
infections[6]
Critical Care Antibiotic Market:
According to "Frost and Sullivan", critical care antibiotics are used in hospital and
intensive care settings to treat patients with 1]:
- Nosocomial or hospital-acquired infections
- Serious community-acquired infections requiring
Critical care antibiotics cost -$62.50 per day, 5 million prescriptions annually. The
bullets below reflect the current reality that the market is dominated by
intravenous/intramuscular injectable antibiotics"*0 .
* Market size (2002) of $3.14 billion growing at 4%
* Market potential (2009) of $3.76 billion at CAGR 3% 101
"Frost and Sullivan" describes the different aspects of antibiotics as follow [101:
" Critical Care Antibiotics are an integral part of life-sustaining or life-saving
technologies.
* Antibiotics: IM / IV injections to treat primary / secondary / nosocomial
infections
Common uses (see figure 8):
" Ventilation: mechanical or machine-assisted ventilation
* Resuscitation: cardiopulmonary resuscitation for patient in cardiac arrest
* Dialysis: may be renal
dialysis, hemodialysis or
peritoneal dialysis.
* Nutrition: includes nutritional
substances and hydration
(tube and IV feeding)
Figure 8: Antibiotic Uses in the Hospital [101
Market Segmentation
Critical Care (Hospital) Antibiotics
Table 5: Market OverviewI
Quinolones, carbapenems and new antibiotics drive the market 03:
Antibiotic Class
Cephalosporins
Quinolnes
Market Size
$ Million
908
1019
2002 1 Growth 2002 %
6.8
Potential
Million
870
1405
2009 $ CAGR
2009
% 2003-
-0.6
4.7
Penicillins 1474 2 1457 1-0. 5
Carbapenemns 1263 11I 381 1 5.5
Others 479 0.6 1648 1 .4
Total 3143 3760 3
Table 6: Common antibiotic classes 1101
CEPHALOSPORINS
Ancef (Cefazolin)
Cefotan (Cefotetan)
Claforan (Cefotaxime)
Fortaz (Ceftazidime)
Kefzol (Cefazolin)
Maxipime (Cefepime)
Mefoxin (Cefoxitin)
Rocephin (Ceftriaxon
QUINOLONES
Avelox (Moxifloxacin)
Cipro (Ciprofloxacin)
Factive (Gemifloxacin)
Tequin (Gatifloxacin)
PENICILLINS
Timentin (Ticarcillin-Clavulanate)
Unasyn (Ampicillin-Sulbactam)
Zosyn (Piperacillin-Tazobactam)
Only Branded Injectables
Included
CARBAPENEMS
Primaxin (Imipenem-Cilastatin)
Merrem (Meropenem)
Invanz (Ertapenem)
OTHERS
NEWER
Streptogramins: Synercid
(Quinopristin-Dalfopristin
Oxazolidones: Zyvox
(Linezolid)
OLDER
Lincosamides: Cleocin
(Clindamycin)
Glycopeptides: Vancocin
(Vancomycin)
Macrolides: Zithromax
(Azithromycin)
Aminoglycosides: Nebcin
(Tobramycin)
----------------- ---- ! ------------------------------------- 1 ---------------- ! ------------------------------- --------------------------
11 --------- I -----------------------------
Market Shares By Class
15%
8%
33%
N Cephalosporins Quinolones 0 Penicllins U Carbapenemn N Others
Others: Streptogramnins, Oxazolidones. Macrolides, Aminoglycosides, Lincosamides. Tetracyclines. Glycopeptides
Figure 9. Major classes of Antibiotics' Market share 1*0
Few multinational companies dominating
with shrinking major brands per segment
Decreasing in-patient/out-patient ratios
with early transfer to community practice
Group purchase organizational deals in hospitals
with fast increasing reimbursement concerns
Focused injectable antibiotics in critical care
with oral options for step-down therapy
Specialized hospital marketing / selling strategies
Figure 10: Technology and market trends 1101
Figure 11: Growth strategies [101
Chapter 8: Requirements for this Research
Scientific and Clinical Considerations
1. Drug's Molecular Size
2. Dosage
3. Side effects
4. Bio-activity
5. Bio-availability
6. Half Life of the drug
7. Frequency of the Drug prescription
8. Number of doses per day
9. Antibiotic Resistance
10. Physician's input
Business Considerations
1. Market Size
2. Dosage Price
3. Patent status (how many years left on the patent life)
4. US market
5. Global Market
Buccal Delivery Considerations
1. Limitations of buccal tissue
2. Toxicity
3. Preexisting conditions
4. pH of the mouth
5. Age 2,7,8,10,11]
Best Candidate Drugs for Use in Nano Particle Buccal Patch.
= Assumed 11 mg entering bloodstream per buccal patch
* Platform-compatibility
- Molecular size
- Low dosage
- Non-oral administration
- Market Size
* Patent status
" Side Effects
This investigation started with 150 antibiotics and based on the criteria's mentioned
above reduced the choices down to 4 best candidates
Figure 12: Narrowing down the drug candidates
Name Daily Dose Market Under Patent
1 Terparatide 1 $219M (US 2010) yes
2 Cancidas 5 $611M (US 2010) yes
3 Tygacil 5 $179M (US 2009) yes
4 Enfuvirtide 10 $134M (US 2006) yes
5 Daptomycin 29 $415M (US 2008) yes
6 Gentamycin 9 $140M (US 1990) no
7 Targocid 17 $358M (US 2002) no
8 Rocephin 21 $740M (US 2005) no
9 Colistimethate 21 $15.4M (US 2007) no
10 Ceptaz 21 $42M (US 2008) no
11 Cidofovir 32 $2.6M (US 2002) no
12 Imipenem 21 $25M (US 2011 Q1) no
Table 7, Examples antibiotic that made our second round of filtering
Chapter 9: Final Drug Candidates
Caspofungin (Cancidas)
Caspofungin is an antifungal drug marketed by Merck & Co under the brand name
Cancidas. It is part of a new class of antibiotics called the echinocandins.It works
effectively on Aspergillus and Candida fungi by inhibiting the enzyme P(1,3)-D-Glucan
synthase and thereby destroying the fungal cell wall. Caspofungin is administered
intravenously [.
Infections with
Aspergillus
iNU stin eUects listea
common side effects
Taken daily for 2 weeks Global: $617M (2009) Infections with Candida Low incidence of side
effects including
headache, nausea,
diarrhea, fever, phlebitis
Blood level monitoring $411.84 / dose
when used in
conjunction with certain
drugs
IV infusion over 1 hour Patent Expires in 2015 Other Notes:
Mol. mass 1093.31 Formula
g/mol C52H88N10015
Pros Cons Recommnendation
High demand Slowed CAGR: sales have Very promising drug with the
Large market share slumping with introduction of new lowest dosage of all the
Basal administration echinocandins. antibiotics. Currently there is a
2nd lowest daily dosage large market size, although may
want to look at more recent
trends.
Table 8, summary of Cancidas investigationt I
Caspofungin acetate for injection was originally approved in 2001. Its approved
indications include the fungal infections in febrile, neutropenic adult patients and the
treatment of invasive aspergillosis in adult patients whose fungal infection does not
respond to other antifungal drugs (i.e., conventional or lipid formulations of amphotericin
B and/or itraconazole). Additionally, the FDA approval includes indication for the
treatment of candidemia and some specific Candida infections (intra-abdominal
abscesses, peritonitis, pleural cavity infections and oesophagitis) and the EMEA
approval includes indication for the treatment of general invasive candidiasis in adult
patients.
Tigecycline (Tygacil)
A glycylcycline antibiotic, tigecycline marketed by Wyeth under the brand name Tygacil
was given a U.S. FDA fast-track approval on June 17, 2005. It was developed in
response to the growing prevalence of antibiotic resistance in bacteria such as
Staphylococcus aureus and Acinetobacter baumannii. The New Delhi metallo-p-
Lactamase multidrug-resistant Enterobacteriaceae has also shown susceptibility to
tigecycline 2.
IU Tor iniai oose
5/dose 2x a day
Uompiicatea
Skin/Skin
Structure
Infections
NO SKin entects
side effects
Taken twice daily for 2-4 $90.46 / dose Complicated Common side effects: diarrhea,
weeks Intra- nausea and vomiting.
abdominal
Infections
Blood level monitoring IV Other side effects include pain at
the injection site, swelling and
irritation; increased or decreased
heart rate and infections.
Infusion for 30-60 Patent expires April Community- Other Notes:
minutes. 2016 Acquired Not recommended for children
Bacterial and pregnant women.
Pneumonia
Mol. mass 585.65 g/mol Formula C29H39N508
Pros Cons Recommendation: Distant 2nd
Patented until 2016 Relatively small market, At 10 patches daily, this could decrease patient's
Basal administration even though lower than compliance. If dosage per patch could be
Lower dosage than most most, still lots of patches increased it would be a good candidate, albeit in a
to be used relatively small market. Given the 2016 expiration
date, this could be possible.
Table 9, summary of Tigecycline investigation21 , 22).
Tigecycline is bacteriostatic and is a protein synthesis inhibitor. It does this by binding to
the 30S ribosomal subunit of bacteria and thereby blocking entry of Aminoacyl-tRNA
into the A site of the ribosome during prokaryotic translation. Tigecycline is administered
intravenously and fights against some of gram-positive and gram-negative bacteria
pathogens, which most are resistant to existing antibiotics. In phase 3 clinical trials it
shows effectiveness similar or better than intravenous vancomycin and aztreonam. It
was to treat complicated skin and skin structure infections (cSSSI), and to intravenous
imipenem and cilastatin to treat complicated intra-abdominal infections (clAl) [2122].
Tigecycline is active against many Gram-positive bacteria, Gram-negative bacteria and
anaerobes - including activity against methicillin-resistant Staphylococcus aureus
(MRSA), Stenotrophomonas maltophilia, Haemophilus influenzae, and Neisseria
gonorrhoeae (with MIC values reported at 2mcg/mL) and multi-drug resistant strains of
Acinetobacter baumannii. It has no activity against Pseudomonas spp. or Proteus spp.
The drug is licenced for the treatment of skin and soft tissue infections as well as intra-
abdominal infections 22].
Tigecycline is slowly administered over 30 to 60 minutes by intravenous infusion. A
single dose of 100 mg is given first, followed by 50 mg every twelve hours after that.
Patients with impaired liver function need to be given a lower dose. No adjustment is
needed for patients with impaired kidney function. It is not licensed for use in children
and there is no oral form available [22].
Enfuvirtide (Fuzeon)
Enfuvirtide is an HIV fusion inhibitor, the first of a novel class of antiretroviral drugs used
in combination therapy for the treatment of HIV-1 infection. Roche is currently markets it
under the trade name Fuzeon. The average annual cost of treatment with this drug in
the US is $25,000. Due to its cost and inconvenient dosing regimen it is used as a
"salvage" therapy in patients with multi-drug resistant HIV [25, 26, 27].
(2006)
Global: $249 million (2006)
common, recommended to use
different sites for every injection
Taken as long as $35 / dose ($25000/year) Peripheral neuropathy, insomnia,
patient benefits depression, cough, dyspnoea,
anorexia, arthralgia, infections ,
and eosinophilia
No blood-level tests Patent Expires June 2013
Bolus subcutaneous Other Notes:
injection Its cost and inconvenient dosing
regimen are factors limiting its
use to a reserve medication.
Mol. mass 4492.1 Formula
g/mol C202H298N50064
Pros Cons Recommendat ion
Potentially taken Common to have skinlittlestimeatodsol
Patened unil 213 20patchs/da
contnuouly or lfe eactonsIt is thought that the market is currently limited due
Patetedunti 203 2 pathesdayto the poor delivery system, which could make it a
good match for Privo. However, the drug causes
Bolus injection skin reactions which could be problematic for
trans-mucosal delivery and the 20 sticks of gum
daily exceeds Privo's stated maximum. The patent
expires in 2 years, leaving little time to solve these
issues.
Table 10, summary of Enfuvirtide investigation 1 25. 26,2 77
Daptomycin (Cubicin)
Daptomycin is a new peptide antibiotic used for Gram-positive infections and is naturally
found in the soil. Its mainly used for infections caused by multi-resistant bacteria and is
marketed in the United States under the trade name Cubicin (Cubist Pharmaceuticals)
[28, 29, 30]
skin
bKin reactions nave Deen
reported including Stevens-
Johnson syndrome
Taken daily for 7-14 Global: $162m (2011 Q1) Bloodstream Anaphylaxis, gastrointestinal
days infections disorders, musculoskeletal
caused by gram- disorders, respiratory disorders
positive bacteria
Staphylococcus
aureus.
IV infusion for 30mins $129 / dose
Patent Expires in 2017 Other Notes:
Its cost and inconvenient dosing
regimen are factors limiting its
use to a reserve medication.
Mol mass 1619.7 Formula c372H-101 N17026
g/mol
Pros Cons Recommendationi
No reported drug Dosage too high for 11 Best of the Patented Higher-Dose Drugs
resistance mg/patch Daptomycin would be a good candidate due to its
Large market large market and low resistance if the issues of the
Steady growth in Serious skin side effects larger dosage and skin side effects can be
sales over the past 5 resolved.
years
Table 11, summary of Daptomycin investigation2 '29 301
Daptomycin has been currently approved by the FDA for skin and Gram-positive skin
structure infections, such as Staphylococcus aureus bacteraemia and right-sided S.
aureus endocarditis. Unfortunately it cannot be used for the treatment of pneumonia
since it binds tightly to pulmonary surfactant [28].
The effectiveness of Daptomycin is similar to standard therapies (nafcillin, oxacillin,
flucloxacillin or vancomycin) in the treatment of bacteraemia and right-sided
endocarditis caused by Staphylococcus aureus. It was used in a study in Detroit,
Michigan on 53 patients suspected of having MRSA skin or soft tissue infection and the
results were compared to those of vancomycin. The result suggested that Daptomycin
is more effective due to faster recovery from skin and soft tissue infections (4 days
versus 7 days). Although the vancomycin control results were from several years ago
where the general patient treatment was not as advance as now and the dose was
lower than (5mg/dI, compared to the 1Omg/dI or 15mg/dI currently recommended).
Teriparatide (Forteo)
Even though Teriparatide is not an antibiotic, we noticed that it would be a great
candidate for buccal delivery. This drug is a parathyroid hormone in a recombinant form,
used in the treatment of some osteoporosis cases. It is manufactured and marketed by
Eli Lilly and Company. This drug is also available in generic form and is our first choice
for a buccal delivery drug [.
Uobal 6.7vi (vuu)
Global $816.7M (2009)
usieoporosis
treatment
NO SKin eTrecis iistea in common
side effects
Leg cramps, nausea, dizziness,
risk of osteosarcoma
development
Use for up to 2 years $30 / dose
Bolus subcutaneous Patent Expires in 2018 Other Notes:
injection into thigh or Zelos Therapeutics has a nasal
abdomen spray in early stages of clinical
trials (NDA planned for 2012).
Patch formulation undergoing
phase il trials outside of the US
Mol. mass 4117.72 g/mol Formula
C1811H291N55051S2
Pros Cons Recommendatkon
Small dosage Bolus subcutaneous Very promising drug with the lowest dosage, a large
Taken daily administration and growing market, and predicted platform
Taken up to 2 years 2 competing delivery compatibility due to molecule's similarity to insulin.
Market predicted to methods in trials
achieve blockbuster
status ($2billion) by 2018
Table 12, summary of Terparatide investigation[231
Teriparatide is the portion of human parathyroid hormone (PTH), amino acid sequence
1 through 34, of the complete molecule (containing 84 amino acids). Endogenous PTH
is the primary regulator of calcium and phosphate metabolism in bone and kidney. PTH
increases serum calcium, partially accomplishing this by increasing bone resorption.
Thus, chronically elevated PTH will deplete bone stores. However, intermittent exposure
to PTH will activate osteoblasts more than osteoclasts. Thus, once-daily injections of
Teriparatide have a net effect of stimulating new bone formation leading to increased
bone mineral density [23
Teriparatide is the first, and to date only, FDA approved agent for the treatment of
osteoporosis that stimulates new bone formation [23].
Concluding Remarks
The buccal antibiotic delivery offers clinician and health care insurers an effective
alternative to reduce hospital associated infections. Furthermore, the high patient
compliance rate, the increasing need of the clinical and market community for
antimicrobials, the physiological advantages of the buccal tissue and GI track and IV
drug delivery limitations, create beneficial conditions for delivering certain broad
spectrum antibiotics via the buccal patch [7, 8,10, 11].
The properties of the buccal mucosa make it well positioned for controlled drug delivery
over extended periods of time. Such properties include the highly vascular buccal
mucosa membrane as well as avoidance of GI track's harsh environment and the first-
pass metabolism. This area is well suited for a retentive device that patients appear to
accept well [2, 7, 81.
Research shows that the mucosa's local environment and permeability can be
controlled and manipulated with proper formulation and dosing. This makes buccal drug
delivery an attractive alternative for systemic delivery especially compared to the
inefficient oral delivery. Exploring and discovering safe and effective
permeation/absorption enhancers is crucial to the future of buccal drug delivery.
Continued research is essential to making this alternative drug delivery technique
completely achievable in the near future [2,7, 8].
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Appendices
Appendix A: Interviews
Name (Last, First) Title Company
Fleming, Jonathan Partner, Founder Oxford Bio Sciences
Navia,-Manuel Drug Discovery and Development Oxford Bio SciencesNavia, Manuel I----------- - ---------Advisor
-- -- - - - -- -- --- --- -- - ----- -- - -- - -- - - - -- -- - ---- - -- - -- -- - -- - -- -- - -- - -- -- - -- - -- -- - -- - -- -
Bukuras, Mark Account Manager Novartis
Roberts, Dave er ernal Business Operations, NovartisRoberts, Dave Technical R&D-- - oats---------
........ . -........ --------- _j------1ca R & D- - ------------- ----------------------------
I Zion, Todd CEO 1 Smart Cells
de los Pinos, Elisabet CEO Aura Biosciences
--- -- -----------------------------------------.1------------ --
Benny, Ofra Associate Professor of Surgery I Harvard Medical School
---- -- ----- -- ------ -------------- -- - ---------- -------- ------- --- --- - ------------------------------------
Warren, Shaw MD Mass General Hospital
-- -------------- - --------- --------------------------------------------------------- -- -- -- -- -- -- -
Walker, Bruce MD Mass General Hospital
Chari, Raghav PhD Dr. Reddy's Laboratories
Zarur, Andrey VC Partner, Lecturer @ Sloan, MIT Kodiak Venture Partners
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Appendix C: Research Conclusion
Drug Terparatide Daptomycin Cancidas Enfuvirtide Gentamycin Ceptaz Rocephin Colistimethate DoripenemDrg (Forteo) (uen
Mn. dose 0.02 4-6mg/kg 50 90 100 250 250 250 250(in mg) ______ ____ _____
Doses per I 1 1 2 1-3 2to3 1to2 2-4 3day
Bolus or
dinistr Bolus bal and basal Bolus both bolus Bolus basal Basal
ation
It may be
injected into a
If basal, vein over 3 to
what is a 5 minutes or
common/ 30mins 1 2 hours N/A mixed in a hour
acceptable solution and
duration given slowlyinto a vein
over 22 to 23
hours.
Moecular 4117.72 16197086 1213.4 4492 g/mol 477.6 636.6 9 1155 gmol 420.5
Compoun C181H291 C72H1OIN1 C52H88 C202H298 C21H43N50 C22H32 C18H16N8 C58H105N16 C15H24N4
d Formula N55051S2 7026 N10015 N50064 7 N6012S Na207S3- Na5028S5 06S22 3.51-20
Appendix D: Example of Market Analysis
Gentamycin - aminoglycoside antibiotic
1) Synonyms: Gentamycin, Garamycin, Gentiomycin C
2) Doses per day: 1-3, depending on condition. 3-7 mg/kg/day
3) Both bolus and basal administration (basal duration - up to two hours)
4) Molecular Formula and Weight:
1. Molecular Formula:
1. Gentamicin C 1 : C 21 H 43 N 5 0 7
2. Gentamicin C 2: C 20 H 41 N 5 0 7
3. Gentamicin C 1a: C 19 H 39 N 5 0 7
2. Molecular Weight (free base):
1. Gentamicin C 1 = 477.6
2. Gentamicin C 2 = 463.6
3. Gentamicin C Ia = 449.5
5) Toxic and other side effects: yes, nephrotoxic. Blood levels must be monitored.
Loss of hearing, balance, and vision due to vestibular apparatus damage.
6) Price: $0.12/mg
7) Patient type: all, mostly adult
8) Most common uses: gram-negative infections (see more info)
9) Patent: originally Abbot Labs, 1977.
(Wikipedia)
- not given orally due to low absorption from small intestine
- Gentamicin can also be highly nephrotoxic, particularly if multiple doses
accumulate over a course of treatment.
o For this reason gentamicin is usually dosed by body weight.
o Also through and peak serum levels of gentamicin are monitored during
treatment, generally before and after the third dose is infused.
(Merck Manual)
- Labeled Indications
o susceptible bacterial infections, normally gram-negative organisms,
- Pseudomonas,
- Proteus,
- Serratia,
- gram-positive Staphylococcus;
- treatment of bone infections,
- respiratory tract infections,
- skin and soft tissue infections,
- abdominal and urinary tract infections,
- septicemia;
- Dosage, Adults:
o 1.M., 1.V.:
- Conventional: 1-2.5 mg/kg/dose every 8-12 hours
- Once daily: 4-7 mg/kg/dose once daily; some clinicians recommend
this approach for all patients with normal renal function; this dose is
71
at least as efficacious with similar, if not less, toxicity than
conventional dosing
o Brucellosis (100 cases/year): 240 mg (1.M.) daily or 5 mg/kg (l.V.) daily
for 7 days; either regimen recommended in combination with doxycycline
o Cholangitis (Increasing. In 2000, 20.9 per 100,000 men, 6.3 per
100,000 women): 4-6 mg/kg once daily with ampicillin
o Diverticulitis - complicated (312,000 admissions and 1.5 million days
of inpatient care per year): 1.5-2 mg/kg every 8 hours (with ampicillin
and metronidazole)
o Endocarditis (10000 to 15000 new cases/year): Treatment: 3 mg/kg/day
in 1-3 divided doses
o Meningitis (rare):
- Enterococcus sp or Pseudomonas aeruginosa: Loading dose 2
mg/kg, then 1.7 mg/kg/dose every 8 hours (administered with
another bacteriocidal drug)
- Listeria: 5-7 mg/kg/day (with penicillin) for 1 week
o Pelvic inflammatory disease (750,000 cases/year): Loading dose: 2
mg/kg, then 1.5 mg/kg every 8 hours
o Plague (10-15 cases/year): Treatment: 5 mg/kg/day, followed by
postexposure prophylaxis with doxycycline
o Pneumonia, hospital- or ventilator-associated (300,000 cases/year): 7
mg/kg/day (with antipseudomonal beta-lactam or carbapenem)
o Synergy (for gram-positive infections) - numbers difficult to find: 3
mg/kg/day in 1-3 divided doses (with ampicillin)
o Tularemia (<1/1,000,000 people/year): 5 mg/kg/day divided every 8
hours for 1-2 weeks
o Urinary tract infection (8-10 million, but gentamicin used only in most
serious cases): 1.5 mg/kg/dose every 8 hours
disease
Brucellosis
Cholangitis**
Diverticulitis
Endocarditis
PID
Plague
100
38080
312,000
12500
750,000
12
mg/kg/day
5
5
6
3
4.5
5
mg/kg/daylyear
500
190,400
1,872,000
37,500
3,375,000
60
Pneumonia 300,000 7 2,100,000
TOTAL 7,575,460 mg/kg/day of treatment
* Not including synergy, UTI, or meningitis due to lack of good numbers
** based on 140 million men and 140 million women in US
Average Weight in US = 80 kg
Total 606,036,800
mg/day
treatment
Cost = $.12/mg
Total 72,724,416 $/day of treatment
Average time of treatment = 4.5 days
Total $327,259,872 year
Note that this assumes all disease cases will be treated with gentamicin, which is obviously unlikely to be
true.
Appendix E: Example of Clinical interviews
Interview with "Boston Home Infusions" - first on the phone and then by
email.
The minutes from our phone conversation are as follows:
* Jessica said that their nurses don't actually administer the drugs - the patients do
it themselves! The nurses teach them how to do it while they're in the hospital
and then once they're discharged, the nurses visit weekly to check up.
. In the hospital, the nurses insert a "peripherally inserted central catheter" into the
inner elbow of the patient. The patient is totally active with this line in - not bed
ridden at all. When pressed, she said the patients cannot lift anything >5lbs with
the line in and that sometimes rashes develop, etc.
. Some drugs require weekly blood levels to be drawn to determine whether to
adjust the dosage. She didn't really like my question about whether the dosage
range had to be narrow or whether it could allow for variation but it seems like the
drugs that don't require these weekly blood level checks have more of a give re:
dosage.
. The IV antibiotics they 'administer' most commonly are as follows:
1. Cancomycin which is used to treat infections (such as MIRSA). Treatment can
last anywhere between 7 days to 3 months. Dosage has to be accurate because
weekly blood levels are drawn and dosage adjusted accordingly.
2. Ceftriaxone also for infections. Similar info as above.
Total Parenteral Nutrition used for mal-absorption in GI tract. This can be
administered from 1 week to lifetime! Dosage is not quite as important. When I
looked this up afterward, it looks like this is just IV food not antibiotic.
I asked her about some of our top candidates and the good news is they do
see patients on a weekly basis for most of them! I quickly jotted the info in the
columns to the right of assigned market researcher on the Google doc. The top
three drugs listed above are used for -100 patients per week.
* I asked whether she thought the patients would benefit from an antibiotic gum.
She seemed surprised by the idea, so I mentioned insulin chewing gum (since
there are other companies producing that already too). She became skeptical
because she thought the gum mechanism was oral, but I decided not to correct
her and just moved on. In theory, she said, the patients would definitely be into
gum.
. When I asked about bolus vs. gradual injection she said there are several
infusion methods in use: elastomeric device, cadd pump, and something else I
couldn't understand (some sort of tubing). They almost always use the
elastomeric device. (http://www.ncbi.nlm.nih.gov/pubmed/1621729) I think the
rate is 100mL per hour? She said it's definitely not bolus; it goes gradually and
patients do it daily.
She didn't have any idea how much it costs for nurse visits because she's in the
pharmacy department.] later emailed her specific questions about our 6 finalist
candidate drugs and she responded as follows:
1. Approximately how many patients do you administer this drug to on a weekly
basis?
Cancidas - 2-3 pts weekly
Enfuviritide - 0
Tygacil - 2-4 pts
Doripenem - 0-1 pts
Targocid - 0
Ceptaz - If this is Ceftazidime 5-6 pts
2. What is the duration of treatment? And the frequency of patient
administration?
Cancidas - daily admin, up to 6 weeks
Enfuviritide - -
Tygacil - twice daily for 2-4 weeks
Doripenem - three times daily for 2 weeks
Targocid - -
Ceptaz - usually three times daily (can be twice daily) for 2-4 weeks
3. Do you check blood levels weekly? What is the range of drug present in blood
that is acceptable before you have to change the patient's dosage?
Cancidas - no drug level monitoring done
Enfuviritide - -
Tygacil - no drug level monitoring done
Doripenem -no drug level monitoring done
Targocid - -
Ceptaz -no drug level monitoring done
4. Do you see skin irritation from the drug (not just the catheter) near area of
administration?
Nothing stands out in particular on any of these drugs in terms of skin irritation solely
related to the drug. Cancidas - Enfuviritide - Tygacil - Doripenem -Targocid -Ceptaz -
5. What are the main indications for this drug? Is it often taken in concurrence
with something else?
Cancidas - fungal infection, administered alone
Enfuviritide - HIV, yes
Tygacil - skin infections/pneumonia, administered alone
Doripenem - abd infections/pneumonia, administration
Targocid - not currently used here in the US
Ceptaz - skin/bone/abdominal infections, used alone pneumonia, may be used with
another drug
6. Do you use the brand name or generic?
Cancidas - Brand
Enfuviritide - -
Tygacil - Brand
Doripenem - Brand
Targocid - -
Ceptaz - Generic
Appendix F: Examples of some analysis
A CD E F H 5
if basal, what is a
1 lDrug in. dose(mg) Do per da or Basal? comm duration? Molecularweight Formula Toxic and other slde effects
increased risk of osteosarcoma, nausea, leg
2 Terparatide (Forteo) 0.02 1 Bolus 4117.72 g/mol C181H291N5505152 cramps and dizziness
3 Cancides 50 1 basal 1 1213.4 C52H8N10015 some hepatic effects
Diarrhea, nausea and vomiting; Pain atthe
100 mg, then injection site, swelling and irritation;
50 mg/12 increased or decreased heart rate and
4 Tygacil 50 hours basal 30 to 60 mins 585.65 g/mol C29H39N508 infections.
Injection site reactions, peripheral
neuropathy, insomnia, depression, cough,
dyspnota, anorexia, arthralgia, infections
5 Enfuvirtide (Fuzeon) 90 2 Bolus 4492 g/mol C202H298N50064 and/or eosinophilia.
nephrotoxic, blood levels must be checked.
6 Gentamycin 100 ito 3 both 2 hours 477.6 C21H43N507 Possible vestibular apparatus damage
7 Targocid (Teicoplanin) 200 1 both 30 min 164.3 to1907.7 C77H77N9031C12.R (variable) dizziness and headaches, skin rash
8 Cephazolin 25 phlebitis, inflammation, pruritus, rash, fever,
diarrhea, vomiting, abdominal pain,
pseudomembranous colitis, headache,
dizziness, paresthesia, cadidiasis, vaginitis,
9 Ceptaz 250 2 to 3 bolus N/A 636.6 C22H32N6012S2 hemolytic anemia
Rocephin 250 lto2 Bolus 661.59 g/mol C18H16N8Na207S393.5H20 Pain and swellingat injection site, diarrhea,
ncrease in liver enzymes, hives, bloody
10 stool, rash, itching, w ing
Colistimethate 250 2to 4 basal 22 to 23 hours 1155 g/mol C58H105N16Na502SS diarrhea, fever, vomiting, muscle weakness,
trouble breathing, allergic reactions
Doripenem 250 3 Basal 1 hour 420.5 C15H24N406S2 Anaphylaxis, sodium valproate, clostridium
difficile-associated diarrhea, development of
drug-resistant bacteria, pneumonitis with
12 inhalational use
Imipenem 250 basal 20-30 min 299.347g/mol C12H17N304S Nausea and vomiting
Kanamycin 250 2 both 30-60 min 484.5g/mol Clh38n4ol Serious side effects include tinnitus or loss of
hearing, toxicity to kidneys, and allergic
reactions to the drug.
14
15 Lactobionate 250
Oxacillin 250 to 6 Both 40g/mol C19H19N305S Neurotoxic reactions, Renal tubular damage
and interstitial nephritis,
Pseudomembranous colitis, Hepatotoxicity,
characterized by fever, nausea, and vomiting
16 1 1
17 Daptomycin 320 1 basal and bolus 30mins 1619.7086 g/mol C72H101N17026 _
Appendix G: A PK/PD Approach to Antibiotic Therapy
From rxkinetics.com
http://www.rxkinetics.com/antibiotic-pkpd.html
Introduction
Pharmacokinetics (PK) is concerned with the time course of antimicrobial
concentrations in the body, while Pharmacodynamics (PD) is concerned with the
relationship between those concentrations and the antimicrobial effect. Antibiotic dosing
regimens have traditionally been determined by PK parameters only. However, PD
plays an equal, if not more important, role. In this age of increasing antimicrobial
resistance, PD becomes even more important because these parameters may be used
to design dosing regimens which counteract or prevent resistance.
Discussion
The primary measure of antibiotic activity is the minimum inhibitory concentration (MIC).
The MIC is the lowest concentration of an antibiotic that completely inhibits the growth
of a microorganism in vitro. While the MIC is a good indicator of the potency of an
antibiotic, it indicates nothing about the time course of antimicrobial activity.
PK parameters quantify the serum level time course of an antibiotic. The three
pharmacokinetic parameters that are most important for evaluating antibiotic efficacy
are the peak serum level (Cmax), the trough level (Cmin), and the Area Under the
serum concentration time Curve (AUC). While these parameters quantify the serum
level time course, they do not describe the killing activity of an antibiotic.
Integrating the PK parameters with the MIC gives us three PK/PD parameters which
quantify the activity of an antibiotic: the Peak/MIC ratio, the T>MIC, and the 24h-
AUC/MIC ratio. The Peak/MIC ratio is simply the Cpmax divided by the MIC. The T>MIC
(time above MIC) is the percentage of a dosage interval in which the serum level
exceeds the MIC. The 24h-AUC/MIC ratio is determined by dividing the 24-hour-AUC by
the MIC.
Antimicrobial Patterns
The three Pharmacodynamics properties of antibiotics that best describe killing activity
are time-dependence, concentration-dependence, and persistent effects. The rate of
killing is determined by either the length of time necessary to kill (time-dependent), or
the effect of increasing concentrations (concentration-dependent). Persistent effects
include the Post-Antibiotic Effect (PAE). PAE is the persistent suppression of bacterial
growth following antibiotic exposure.
Using these parameters, antibiotics can be divided into 3 categories:
PKIPDPattern of Activity Antibiotics Goal of Therapy
Type I Aminoglycosides
Concentration-dependent Daptomycin Maximize 24h-AUC/MIC
killing and Fluoroquinolones concentrations Peak/MIC
Prolonged persistent effects Ketolides
Type |j Carbapenems Maximize duration of T>MIC
Pharmacokinetic/Pharmacodynamic
Predictors of Efficacy
PK/PD parameters
C__T>MIC
Peak/MIC
24-h AUC/MIC
Area under the curve:
"amou( t of dru
Time (hours)
Time-dependent killing and Cephalosporins exposure
Minimal persistent effects Erythromycin
Linezolid
Penicillins
Azithromycin
Type ll
Clindamycin
Time-dependent killing and Maximize amount ofOxazolidinones 24h-AUC/MIC
Moderate to prolonged drug
Tetracyclines
persistent effects.
Vancomycin
For Type I antibiotics (AG's, fluoroquinolones, daptomycin and the ketolides), the ideal
dosing regimen would maximize concentration, because the higher the concentration,
the more extensive and the faster is the degree of killing. Therefore, the 24h-AUC/MIC
ratio, and the Peak/MIC ratio are important predictors of antibiotic efficacy. For amino
glycosides, it is best to have a Peak/MIC ratio of at least 8-10 to prevent resistance. For
Fluoroquinolone vs gram negative bacteria, the optimal 24h-AUC/MIC ratio is
approximately 125. Versus gram positives, 40 appears to be optimal. However, the ideal
24h-AUC/MIC ratio for FQ's varies widely in the literature.
Type |1 antibiotics (beta-Lactams, clindamycin, erythromycin, and linezolid) demonstrate
the complete opposite properties. The ideal dosing regimen for these antibiotics
maximizes the duration of exposure. The T>MIC is the parameter that best correlates
with efficacy. For beta-Lactams and erythromycin, maximum killing is seen when the
time above MIC is at least 70% of the dosing interval.
Type IlIl antibiotics (vancomycin, tetracycline's, azithromycin, and the dalfopristin-
quinupristin combination) have mixed properties; they have time-dependent killing and
moderate persistent effects. The ideal dosing regimen for these antibiotics maximizes
the amount of drug received. Therefore, the 24h-AUC/MIC ratio is the parameter that
correlates with efficacy. For vancomycin, a 24h-AUC/MIC ratio of at least 125 is
necessary (some researchers recommend a ratio of 400 or more for problem bugs).
Predictors of Bacterial Eradication:
Pharmacokinetlc/Pharmacodynamic Profiles
PeakMIC
(\Kj
- Aminoglycosides
T >MIC
-Beta-lactums
-Clindamycin
-Erythromycin
- Linezolid
24h-AUCMIC
-Arithromycin
- Quinolones
- Vancomycin
Outcome studies
Aminoglycoside Pharmacodynamics in Vivo
Moore et al, J Infect Dis 149: 443, 1984
Aminoglycoside Pharmacodynamics in vivo
Initial serum peak Died Survived
level
< 5mcg/ml 21% 79%
>= 5mcg/ml 2% 98%
Moore et al, J Infect Dis 155: 93, 1987
Vancomycin Outcome vs 24h-AUC/MIC ratio
Hyatt et al, Clin Pharmacokinetic 28: 143, 1995
Fluoroquinolone Pharmacodynamics vs S. pneumonia
Ambrose et al, Antimicrob Agents Chemo 10: 2793, 2001
24h-
AUCIMIC Satisfactory Unsatisfactory
ratio
< 125 4(50%) 4
>1>25 71(97%) 2
24h-AUC/MIC Microbiological
ratio Response
< 33.7 (64%)
> 33.7 (100%)
Pharmacodynamics of Beta-Lactams and Macrolides in Otitis Media
Craig et al, Ped Infect Dis 15: 255, 1996
Conclusion
PK dosing has shown us that one dose is not appropriate for all patients.
Pharmacodynamics shows us that one target level is not appropriate for all patients. We
need to evaluate both the serum level data and the MIC, taking into consideration the
PD properties of the drug.
Numerous outcome studies have shown that class-appropriate PK/PD parameters are
excellent predictors of antibiotic efficacy.
Appendix H: Examples of Interviews with Industry leaders and Venture
Capital Firm
Interview with Dr. Navia, Oxford Biosciences
Finding the Best Drug Candidates for Buccal Delivery
The following is the brief description for Privo's market needs:
1) Look into several different drug classes such as antibiotics, hormones
(growth,...), cancer drugs, vaccines and HIV.
2) Find out from clinical experts in each field, what the ideal candidates drugs are
for Privo's platform technology (endocrinologist for diabetes and hormones,
infectious disease for antibiotics,...)
3) Examples could be FUZEON (enfuvirtide) for HIV, Insulin for diabetes, growth
hormone, polio for vaccines and ....
4) See which drugs within each class has the following principle requirements:
a. Replacing injection for buccal delivery would be a great benefit to the
patient
b. Big market demand, get the market size
c. What would appropriate prices
d. Could reduce the cost of "Step Down": in-between hospital to home
transition
e. Find out the Risk/Benefit ratio
f. Find out the patient compliance benefits
g. Find out the dosage for each drug
h. We can then figure out if we can fit the required dose in the gum or
lozenges
Minutes of meeting with Dr. Martyn Botfiled
Aug 09, 2010, lunch meeting at 4 burgers, Cambridge, Ma
Attendees: Martyn Botfield, Manijeh Goldberg, arranged via Beth Edwards (my mentor
at Vertex)
Martyn Botfield, PhD
Senior Director & Global Head,Biomarker Research & Translational
Pharmacology
Vertex Pharmaceuticals, 130 Waverly St,Cambridge MA 02136,617.444.6375
(office)
Martyn received his PHD in BioChemistry from Harvard and has been a
professor at Harvard medical School teaching HST students.
1) Martyn was concerned that mucosa drug delivery is a poisoned well because of
Pfizer's Exubera
2) He said that making a safe and acceptable bio-available solution for insulin and
other drugs is not a trivial job and anyone dealing with pharma understands the
complexity of it.
3) The FDA will not directly talk to you and give you advice because of regulations
4) The FDA will only comment if you have written them a proposal and they will say
what things they do not approve, but will not give you reasons in most cases.
5) Usually you can ask questions from FDA consultants
6) He said he will try to contact some one that might help with contacting Eli Lilly
7) He said look into Orasure a company for oral HIV test
8) Martyn suggested creating a charitable cause for doing oral drug delivery, insulin
9) Martyn said that I can call him and ask any questions or just give him updates on
a regular basis
1 O)See if you can make a HCV test for Marines with the chewing gum
1 1)Make a collection Chewing gum and not just a delivery gum:
a. This can be a once a month gum indicating metabolic disorders,
proteins,...
b. Defense department will be very interested in this
c. Talk to a VA hospital about their needs
d. Collects saliva and DNA
e. Having the DNA ensures that the user cannot cheat and use someone
else's gum
f. Could Indicate any usage of addictive substances
g. Could Indicate Hepatitis C virus
h. Could Indicate other type of war related diseases
i. Could Indicate Post Traumatic Syndrome
j. Could indicate any other toxins in the air/water that the soldiers are
exposed to.
k. See if you can make a gum that can sustain the content, proteins, saliva,
bacteria and soon, put the gum in a specific container and ship it to a lab
